Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000651

Drug Information
NameTeniposide
Synonyms4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside); Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); Vumon; MolPort-003-666-525; BRD-A35588707-001-02-2; CID6708778; CID107642; Spectrum_001549; CID275784; I06-2040; KST-1A3576; KBio2_007165; HMS2093O15; D02698; 29767-20-2; KBio3_002939; Vumon (TN); KBioGR_001050; LS-63999; DB00444; CID5284623; 55256-09-2; AC1L32H7; Teniposide [USAN:BAN:INN]; Teniposidum; AC1L1K9H; FT-0080118; Ambap29767-20-2; VM 26; KBio1_001832; NCI60_000540; Teniposido [INN-Spanish]; Spectrum5_001111; KBio2_004597; Epipodophyllotoxin-beta-D-thenylidene-glucoside, 4'-demethyl-; BSPBio_003436; CID5396; MLS000766234; AC1L5IF3; Spectrum2_001647; Vumon, VM-26, Vehem, NSC 122819, Teniposide; Teniposido; 4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside; KBioSS_002029; Vehem; Neuro_000056; teniposide; EINECS 249-831-2; AR-1A6252; 4'-Demethylepipodophyllotoxin-beta-D-thenylidine glucoside; C32H32O13S; CID34698; Veham-Sandoz; Vee M-26; S1787_Selleck; Spectrum3_001898; 35317-44-3; CHEMBL278534; AC1L9QDK; PTG; NSC 122819; Spectrum4_000585; Demethyl Epipodophyllotoxin Thenylidine Glucoside; KST-1A5976; VM-26; HMS1922B15; SPBio_001773; AR-1A6526; DivK1c_006888; Teniposidum [INN-Latin]; HSDB 6546; Teniposide (USAN/INN); 31514-29-1; MolPort-005-940-276; CCRIS 2058; NSC 12819; SpecPlus_000792; SPECTRUM1504094; C11153; 4'-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); AC1NR4S8; 4'-Demethylepipodophyllotoxin thenylidene glucoside; CID452548; AC1L1S3X; AC1O8FOE; 4-Demethylepipodophyllotoxin-.beta.-D-thenylideneglucoside; KBio2_002029; UNII-957E6438QA; 23362-13-2; NSC122819; AC-759; MolPort-006-822-656; 4'-Dimethyl-9-(4,6-O-2-thenyid)-epipodophyllotoxin; 299-36-5; NSC-122819; SMR000528847
Trade NameVumon; VM-26
IndicationAcute lymphocytic leukemia
[ICD9: 204.0   ICD10: C91.0]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-1
2-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-2
1(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-3
5H,10-12H2,1-2H3
InChIKeyNRUKOCRGYNPUPR-UHFFFAOYSA-N
Canonical SMILESCOC1=CC(=CC(=C1O)OC)C2C3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)OC6C(C(C7C(O6)COC
(O7)C8=CC=CS8)O)O    
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 29767-20-2
FormulaC32H32O13S
PubChem Compound IDCID 5396.
PubChem Substance IDSID 5639773.
SuperDrug ATC IDL01CB02
SuperDrug CAS ID029767202;
TargetDNA topoisomerase IIInhibitor[2]
Ref 1Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. To Reference
Ref 2Topoisomerases: therapeutic value. Ann Pharm Fr. 1996;54(1):40-4. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543